Como complemento de los agonistas de la dopamina | 06 SEP 19
Rasagilina en la enfermedad de Parkinson
La rasagilina ha demostrado su eficacia como monoterapia, como un complemento de los agonistas dopaminérgicos y como un complemento de la L-dopa en pacientes que experimentan fluctuaciones motoras
Autor/a: Hauser R.A., Silver D. y colaboradores Mov Disord. 2014 Jul;29(8):1028-34
Texto principal
- Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-1053.
- Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484-1491.
- Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH. A reassessment of risks and benefits of dopamine agonists in Parkin- son’s disease. Lancet Neurol 2009;8:929-937.
- Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006;63:969-973.
- Perez-Lloret S, Rey MV, Fabre N, et al. Prevalence and pharmaco- logical factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clin Neuropharmacol 2012;35: 261-265.
- Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkin- son disease. Arch Neurol 2006;63:1756-1760.
- Olanow CW, Kieburtz K, Rascol O, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord 2013;28:1064-1071.
- Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 2006;7:295-309.
- Fahn S, Elton RL. Unified Parkinson’s Disease Rating Scale. Recent developments in Parkinson’s disease: MacMillan Healthcare Infor- mation, 1987:153-164.
- Doty RL, Marcus A, Lee WW. Development of the 12-item cross- cultural smell identification test (CC-SIT). Laryngoscope 1996;106: 353-356.
- Marinus J, Visser M, Verwey NA, et al. Assessment of cognition in Parkinson’s disease. Neurology 2003;61:1222-1228.
- Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the devel- opment, validation and application of a Parkinson’s disease quality of life questionnaire and its associated measures. J Neurol 1998; 245[Suppl 1]:S10-S14.
- Guy W. Clinical global impressions. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: Department of Health, Education, and Welfare, Washington, DC, 1976:218-222.
- Marinus J, Visser M, van Hilten JJ, Lammers GJ, Stiggelbout AM. Assessment of sleep and sleepiness in Parkinson disease. Sleep 2003;26:1049-1054.
- Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically important change on the un
Comentarios
Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024